enGene Therapeutics Inc. (ENGN) stock
ENGNNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends October 31Also trades as ENGNW
Số liệu tài chính tới Q3 năm tài chính 2026, quý kết thúc ngày Jul 31, 2026Last filing: 10-Q on Sep 8, 2026Score 3/30
$1.72−0.17 (-8.99%)
Close on Nov 17, 2026Market cap $115.27MP/E –Yield 0.00%
enGene Therapeutics enterprise value
Enterprise value is market cap plus debt, minus cash: the value of the whole business to all its investors.
enGene Therapeutics's enterprise value was -$120.54M on Nov 11, 2026, against $228.22M a year earlier. Over the last 4 years it ranged from -$138.63M to $347.50M, with a median of $38.58M.
Enterprise Value at the end of each year
| Period | Period end | Value | Change |
|---|---|---|---|
| 2026 | Nov 11, 2026 | -$120.54M | -141.4% |
| 2025 | Dec 31, 2025 | $291.32M | +136.6% |
| 2024 | Dec 31, 2024 | $123.14M | -13.2% |
| 2023 | Dec 29, 2023 | $141.81M | – |
| 2022 | Dec 30, 2022 | -$3.91M | – |
See a number that looks wrong?